State Street’s Xenetic Biosciences XBIO Stock Holding History

State Street’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,467	Closed	-$14.3K	–	4727
2023 Q1	$14.3K	Hold	3,467	–	–	﹤0.01%	4718
2022 Q4	$9.91K	Hold	3,467	–	–	﹤0.01%	4807
2022 Q3	$19K	Hold	3,467	–	–	﹤0.01%	4837
2022 Q2	$28K	Hold	3,467	–	–	﹤0.01%	4833
2022 Q1	$35K	Buy	3,467 +77	+2%	+$803	﹤0.01%	4850
2021 Q4	$44K	Hold	3,390	–	–	﹤0.01%	4715
2021 Q3	$69K	Buy	+3,390	New	+$92.4K	﹤0.01%	4612

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street's XBIO Position: Q2 2023 in Review

State Street sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 3,467 shares — an estimated $14.3K sold.

State Street first reported a position in XBIO in Q3 2021 and held it in 7 quarters. The position peaked at $69K in Q3 2021. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

State Street reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
State Street sold 3,467 Xenetic Biosciences shares in Q2 2023, an estimated $14.3K.
State Street first reported a position in Xenetic Biosciences in Q3 2021 and held it in 7 quarters.
State Street's Xenetic Biosciences position peaked at $69K in Q3 2021.
9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.